JP2020512350A - ニラパリブ組成物 - Google Patents

ニラパリブ組成物 Download PDF

Info

Publication number
JP2020512350A
JP2020512350A JP2019553055A JP2019553055A JP2020512350A JP 2020512350 A JP2020512350 A JP 2020512350A JP 2019553055 A JP2019553055 A JP 2019553055A JP 2019553055 A JP2019553055 A JP 2019553055A JP 2020512350 A JP2020512350 A JP 2020512350A
Authority
JP
Japan
Prior art keywords
indazole
piperidin
phenyl
carboxamide
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019553055A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020512350A5 (enExample
Inventor
ジョージ、ウー
ジョン、チャバー
Original Assignee
テサロ， インコーポレイテッド
テサロ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63676949&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2020512350(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by テサロ， インコーポレイテッド, テサロ， インコーポレイテッド filed Critical テサロ， インコーポレイテッド
Publication of JP2020512350A publication Critical patent/JP2020512350A/ja
Publication of JP2020512350A5 publication Critical patent/JP2020512350A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2019553055A 2017-03-27 2018-03-27 ニラパリブ組成物 Pending JP2020512350A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762477411P 2017-03-27 2017-03-27
US62/477,411 2017-03-27
PCT/US2018/024603 WO2018183354A1 (en) 2017-03-27 2018-03-27 Niraparib compositions

Publications (2)

Publication Number Publication Date
JP2020512350A true JP2020512350A (ja) 2020-04-23
JP2020512350A5 JP2020512350A5 (enExample) 2021-05-06

Family

ID=63676949

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019553055A Pending JP2020512350A (ja) 2017-03-27 2018-03-27 ニラパリブ組成物

Country Status (14)

Country Link
US (3) US11091459B2 (enExample)
EP (1) EP3600314A1 (enExample)
JP (1) JP2020512350A (enExample)
KR (1) KR20200014736A (enExample)
CN (1) CN110944638A (enExample)
AU (2) AU2018246214B2 (enExample)
BR (1) BR112019020211A2 (enExample)
CA (1) CA3058375C (enExample)
EA (1) EA201992177A1 (enExample)
IL (1) IL269630A (enExample)
MX (1) MX2019011496A (enExample)
SG (1) SG11201909011PA (enExample)
TW (1) TWI761476B (enExample)
WO (1) WO2018183354A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX394062B (es) 2016-06-29 2025-03-19 Tesaro Inc Métodos para el tratamiento del cáncer ovárico.
KR20200014736A (ko) 2017-03-27 2020-02-11 테사로, 인코포레이티드 니라파립 조성물
SG11201909807TA (en) 2017-04-24 2019-11-28 Tesaro Inc Methods of manufacturing of niraparib
KR20200018436A (ko) 2017-05-09 2020-02-19 테사로, 인코포레이티드 암 치료를 위한 조합 요법
CA3063715A1 (en) 2017-05-18 2018-11-22 Tesaro, Inc. Combination therapies for treating cancer
KR20250016494A (ko) 2017-09-26 2025-02-03 테사로, 인코포레이티드 니라파립 제제
MX2020003770A (es) 2017-09-30 2020-07-29 Tesaro Inc Terapias de combinacion para tratar cancer.
CA3076859A1 (en) 2017-10-06 2019-04-11 Tesaro, Inc. Combination therapies and uses thereof
RU2020129236A (ru) 2018-02-05 2022-03-09 Тесаро, Инк. Педиатрические препараты нирапариба и способы лечения в педиатрии
EP3860988A1 (en) 2018-10-03 2021-08-11 Tesaro, Inc. Crystalline forms of niraparib freebase
WO2020072860A1 (en) 2018-10-05 2020-04-09 Johnson Matthey Public Limited Company Niraparib solid state form
CA3087392A1 (en) 2019-07-16 2021-01-16 Apotex Inc. Crystalline forms of niraparib tosylate
WO2021224469A1 (en) 2020-05-08 2021-11-11 Janssen Pharmaceutica Nv Treatments of prostate cancer with combinations of abiraterone acetate and niraparib
EP4373491A1 (en) 2021-07-19 2024-05-29 JANSSEN Pharmaceutica NV Treatment of metastatic castration-resistant prostate cancer with niraparib
CN119156216A (zh) 2022-02-15 2024-12-17 特沙诺有限公司 尼拉帕尼用于治疗脑癌的用途
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
EP4532493A1 (en) 2022-06-01 2025-04-09 Ideaya Biosciences, Inc. Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof
WO2024238587A1 (en) 2023-05-17 2024-11-21 Tesaro, Inc. Novel use of an inhibior of the a poly-adp ribose polymerase (parp) in the treatment of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010515715A (ja) * 2007-01-10 2010-05-13 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
JP2011509252A (ja) * 2008-01-08 2011-03-24 メルク シャープ エンド ドーム リミテッド ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩
US20150029916A1 (en) * 2013-07-23 2015-01-29 Disney Enterprises, Inc. Power Saving for Multi-Hop Communications

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0606663D0 (en) 2006-04-03 2006-05-10 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2007113596A1 (en) 2006-04-03 2007-10-11 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors
WO2008043024A2 (en) 2006-10-04 2008-04-10 Kalypsys, Inc. Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease
EP2212296B1 (en) * 2007-10-17 2014-12-03 Kudos Pharmaceuticals Limited 4- [3- (4-cyclopropanecarbonyl-piperazine-i-carbonyl) -4 -fluoro-benzyl]-2h-phthalaz in-1-one
US20100278921A1 (en) 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
JP2013503173A (ja) * 2009-08-26 2013-01-31 セファロン、インク． 多環系化合物の新規形態
CA2779052A1 (en) 2012-05-31 2013-11-30 Pharmascience Inc. Pharmaceutical composition of entecavir and process of manufacturing
EP2928473B1 (en) 2012-12-07 2017-06-28 Merck Sharp & Dohme Corp. Regioselective n-2 arylation of indazoles
WO2014088984A1 (en) 2012-12-07 2014-06-12 Merck Sharp & Dohme Corp. Biocatalytic transamination process
AU2014251038A1 (en) 2013-04-08 2015-11-26 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
CN106458935B (zh) 2014-01-05 2019-05-28 华盛顿大学 用于聚(adp-核糖)聚合酶-1(parp-1)的放射性标记示踪物，其方法和用途
US20150299219A1 (en) 2014-04-22 2015-10-22 Calitor Sciences, Llc Bicyclic pyrazolone compounds and methods of use
WO2015184145A1 (en) 2014-05-28 2015-12-03 Eisai R&D Management Co., Ltd. Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
AU2015305696B2 (en) 2014-08-22 2019-08-29 Pharma& Schweiz Gmbh High dosage strength tablets of rucaparib
EP3230472A4 (en) 2014-12-08 2018-06-13 Myriad Genetics, Inc. Methods and materials for predicting response to niraparib
WO2017002095A1 (en) 2015-07-02 2017-01-05 Acerta Pharma B.V. Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
MX394062B (es) 2016-06-29 2025-03-19 Tesaro Inc Métodos para el tratamiento del cáncer ovárico.
CN106496187A (zh) * 2016-09-14 2017-03-15 陕西科技大学 一种制备PARP抑制剂Niraparib的合成方法
CN106831708A (zh) 2016-11-22 2017-06-13 西安泰科迈医药科技股份有限公司 一种新型口服抗癌药物Nirapairb的合成方法
CN108201537A (zh) 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种尼拉帕尼缓控释药物组合物及其用途
CN106854176A (zh) 2016-12-21 2017-06-16 南京艾德凯腾生物医药有限责任公司 一种制备尼拉帕尼对甲苯磺酸盐一水合物的方法
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
EP3606523A1 (en) 2017-03-27 2020-02-12 Tesaro, Inc. Niraparib formulations
KR20200014736A (ko) 2017-03-27 2020-02-11 테사로, 인코포레이티드 니라파립 조성물
SG11201909807TA (en) 2017-04-24 2019-11-28 Tesaro Inc Methods of manufacturing of niraparib
KR20200018436A (ko) 2017-05-09 2020-02-19 테사로, 인코포레이티드 암 치료를 위한 조합 요법
CA3063715A1 (en) 2017-05-18 2018-11-22 Tesaro, Inc. Combination therapies for treating cancer
CN108530425A (zh) 2017-05-27 2018-09-14 广州科锐特生物科技有限公司 一种尼拉帕尼对甲苯磺酸盐水合物晶型及其制备方法
KR20250016494A (ko) 2017-09-26 2025-02-03 테사로, 인코포레이티드 니라파립 제제
MX2020003770A (es) 2017-09-30 2020-07-29 Tesaro Inc Terapias de combinacion para tratar cancer.
CA3076859A1 (en) 2017-10-06 2019-04-11 Tesaro, Inc. Combination therapies and uses thereof
TW201929902A (zh) 2017-12-27 2019-08-01 美商提薩羅有限公司 治療癌症之方法
RU2020129236A (ru) 2018-02-05 2022-03-09 Тесаро, Инк. Педиатрические препараты нирапариба и способы лечения в педиатрии
EP3860988A1 (en) * 2018-10-03 2021-08-11 Tesaro, Inc. Crystalline forms of niraparib freebase
CA3087392A1 (en) * 2019-07-16 2021-01-16 Apotex Inc. Crystalline forms of niraparib tosylate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010515715A (ja) * 2007-01-10 2010-05-13 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
JP2011509252A (ja) * 2008-01-08 2011-03-24 メルク シャープ エンド ドーム リミテッド ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩
US20150029916A1 (en) * 2013-07-23 2015-01-29 Disney Enterprises, Inc. Power Saving for Multi-Hop Communications

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHUNG, C. K. ET AL.: "Process Development of C-N Cross-Coupling and Enantioselective Biocatalytic Reactions for the Asymme", ORG. PROCESS RES. DEV., vol. 18, JPN6021017715, 2014, pages 215 - 227, ISSN: 0004687329 *
WALLACE, D. J. ET AL.: "Development of a Fit-for-Purpose Large-Scale Synthesis of an Oral PARP Inhibitor", ORG. PROCESS RES. DEV., vol. 15, JPN6021017717, 2011, pages 831 - 840, ISSN: 0004506574 *
厚生省医薬安全局審査管理課長: "医薬品の残留溶媒ガイドラインについて", 医薬審, vol. 第307号, JPN6014031669, 1998, pages 1 - 11, ISSN: 0004687333 *
小嶌隆史: "医薬品開発における結晶形選択の効率化を目指して", 薬剤学, vol. 68, no. 5, JPN6009053757, 1 September 2008 (2008-09-01), pages 344 - 349, ISSN: 0004687331 *
平山令明編, 有機化合物結晶作製ハンドブック −原理とノウハウ−, JPN6011053065, 25 July 2008 (2008-07-25), pages 57 - 84, ISSN: 0004687332 *
高田則幸: "創薬段階における原薬Formスクリーニングと選択", PHARM STAGE, vol. 6, no. 10, JPN6009053755, 15 January 2007 (2007-01-15), pages 20 - 25, ISSN: 0004687330 *

Also Published As

Publication number Publication date
WO2018183354A1 (en) 2018-10-04
SG11201909011PA (en) 2019-10-30
TWI761476B (zh) 2022-04-21
US20230416223A1 (en) 2023-12-28
CA3058375A1 (en) 2018-10-04
CN110944638A (zh) 2020-03-31
US11673877B2 (en) 2023-06-13
IL269630A (en) 2019-11-28
AU2018246214B2 (en) 2021-07-08
US20200017462A1 (en) 2020-01-16
MX2019011496A (es) 2020-01-23
US11091459B2 (en) 2021-08-17
TW201840315A (zh) 2018-11-16
AU2021245223A1 (en) 2021-11-04
CA3058375C (en) 2025-05-06
US20210403448A1 (en) 2021-12-30
EP3600314A1 (en) 2020-02-05
BR112019020211A2 (pt) 2020-04-22
KR20200014736A (ko) 2020-02-11
AU2018246214A1 (en) 2019-11-07
EA201992177A1 (ru) 2020-02-25

Similar Documents

Publication Publication Date Title
US11673877B2 (en) Niraparib compositions
JP7269227B2 (ja) ニラパリブ処方物
US20220331305A1 (en) Pharmaceutical Compositions Comprising Alpelisib
EP2809305B1 (en) Bilayer tablet formulations of flurbiprofen and glucosamin
KR20240155526A (ko) 엔잘루타마이드를 포함하는 무정형 고체 분산체, 그를 포함하는 경구 투여용 약제학적 제제
KR20240040407A (ko) 사쿠비트릴ㆍ발사르탄 칼슘염을 포함하는 약제학적 조성물
RU2452476C2 (ru) Производные 1-аминоалкилциклогексана для лечения и предупреждения потери слуха
EA044464B1 (ru) Таблетка для ингибирования полиаденозин дифосфат рибоза полимеразы (parp)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210326

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210326

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20210416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210514

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210810

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220121